Investigators who are writing grant applications and need descriptions of the Preclinical Modeling core’s patient-derived xenograft (PDX) and genetically engineered mouse model (GEMM) teams can find them below. Descriptions of the overall Fred Hutchinson Cancer Center Shared Resources program are available on the main Shared Resources grant information page.
Publications by PM staff are listed below.
All publications, press releases, or other documents that cite results from CCSG-supported research must include acknowledgement of the grant and maintain compliance with NIH Public Access Policy. All manuscripts accepted for publication must be submitted to PubMed Central and be assigned a PMCID. Additionally, please reference the Research Resource Identifier (RRID). RRIDs are assigned to cores to help researchers cite key resources in the biomedical literature to improve transparency of research methods.
“This research was supported by the Preclinical Modeling Shared Resource, RRID:SCR_022617, of the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium (P30 CA015704).”
Our patient-derived xenograft (PDX) services, part of the Preclinical Modeling shared resource (PM), support researchers in tumor tissue collection, development, propagation and banking of PDX tumors and management of data. We have more than 60 banked PDX tumor models. Based on growth trajectories, we will house approximately 100 models by 2022. Dedicated PDX staff provide full-service preclinical study assistance, including PDX mouse model creation, experimental agent testing, and data collection and reporting. The PDX team maintains multiple well-established breeding colonies of NSG and NSG hprt-null mice within the AAALAC-accredited Fred Hutch animal facility.
The Preclinical Modeling shared resource (PM), enables preclinical research at Fred Hutch through its two arms: the patient-derived xenograft (PDX) team and the genetically engineered mouse model (GEMM) team. The PM core maintains its operations within Fred Hutch’s Comparative Medicine shared resource. This association provides the PM core with state-of-the-art housing, veterinary care and oversight and laboratory space within an AAALAC-accredited animal facility. PM occupies two barrier mouse housing rooms, one biosafety level 2 mouse housing room, and two dedicated procedure spaces in the Hutchinson Building on the Fred Hutch campus. The PM shared resource is partially supported by a National Cancer Institute Cancer Center Support Grant to the Fred Hutch/University of Washington Cancer Consortium.
The PDX team provides researchers with assistance ranging from project discussion to complete therapeutic trials in PDX mouse models. Currently, the PDX team's tumor bank houses more than 60 PDX models. Based on growth trajectories, it will house approximately 100 models by 2022. Available equipment includes: a Leica M60 stereomicroscope, an automated EVOS cell counter, an EVOS FL monochrome microscope, -20oC and -80oC freezers, and two liquid nitrogen cryogenic dewars with six canisters. The team supports PDX-related studies for multiple investigators within the Cancer Consortium.
PDX Model Creation: Harnessing the PM’s well-established infrastructure, the PDX team can support the development of patient tumor tissue as PDX mouse models, with services including implantation, serial repassaging, characterization and banking.
PDX Model Acquisition: The team helps to source and coordinate acquisition of established PDX models from third parties, such as the Jackson Laboratory and the National Institutes of Health’s Patient-Derived Models Repository. These models are revived from their cryopreserved state, implanted and serially repassaged to expand and establish the model, and then used to implant cohorts of mice for treatment studies.
Mouse Breeding and Distribution Services: The PDX team's specialized support includes an NSG mouse breeding colony and an NSG hprt-null breeding colony. Having NSG mice on hand allows the team to react rapidly to dynamic situations — from implanting patient samples to repassaging — at a subsidized cost. The PDX team also maintains cryopreserved NSG hprt-null mice. This strain permits the in vitro isolation of human cells using HAT selection medium to eliminate mouse cells from mouse-passaged PDX samples, thus ensuring new patient-derived cell lines are human cell-only.
Banking Services: The PDX team has short-term cryogenic storage space available in the core lab (liquid nitrogen rolling dewars) and can facilitate long-term storage (liquid nitrogen with emergency backup). The core’s own PDX repository is split across two locations for safety.
Training: The core's PDX staff are also available to train lab members on PDX procedures and to advise on the generation and maintenance of PDX models and on preclinical trial design.
The PDX support team has decades of combined experience in working with mouse models of cancer. The Comparative Medicine core and research animal facility, which supports the PM core’s animal work at the Hutch, is fully accredited by AAALAC International and complies with all U.S. Department of Agriculture, Public Health Service, Washington state and local area animal welfare regulations.
The genetically engineered mouse modeling (GEMM), services at Fred Hutch support investigators through resources and expertise in the design, production and maintenance of transgenic and gene-edited mice. The ability of the GEMM team to manipulate the mouse genome through CRISPR and traditional transgenic technology is invaluable in studying the functions of genes relevant to cancer and other human diseases. The team provides state-of-art mouse genetic manipulations and other critical services for mouse colony production and preservation such as in vitro fertilization, mouse and embryo cryopreservation, speed expansion of mouse colonies and mouse strain rederivation services.
The Preclinical Modeling shared resource (PM), enables preclinical research at Fred Hutch through its two arms: the patient-derived xenograft (PDX) team and the genetically engineered mouse model (GEMM) team. The PM core maintains its operations within Fred Hutch’s Comparative Medicine shared resource. This association provides the PMCL with state-of-the-art housing, veterinary care and oversight and laboratory space within an AAALAC-accredited animal facility. The PM shared resource occupies two barrier mouse housing rooms, one biosafety level 2 mouse housing room, and two dedicated procedure spaces in the Hutchinson Building on the Fred Hutch campus. The PM core is partially supported by a National Cancer Institute Cancer Center Support Grant to the Fred Hutch/University of Washington Cancer Consortium.
The GEMM team supports investigators through resources and expertise in the design, production and maintenance of transgenic and gene-edited mice. The staff works with investigators to adapt and develop novel technology to create genetically engineered mouse models of varying complexity. The ability of the GEMM team to manipulate the mouse genome by pronuclear and cytoplasmic microinjection into one-cell mouse embryos is invaluable for studying the functions of genes relevant to cancer and other human diseases.
The GEMM team offers a wide range of services requisite for transgenic mouse production and mouse colony management, and it is equipped with all essential expertise, instrumentation and procedure spaces. The basic molecular biology lab (272 sq. ft.), located within the Comparative Medicine facility, is equipped with all basic instruments essential for the operation of the CRISPR/Cas9 tool (E-Gel Imager, nanophotometer, agarose gel electrophoresis system, -80oC and -20oC freezers, 37oC incubator, and water bath, thermal cyclers, etc.). This setup permits the GEMM team to provide screening assays and genotyping of complex founder animals, vector creation, quality control and quick adoption of novel techniques. A dedicated procedure space within the animal facility (specific pathogen-free space: 135 sq. ft.) is equipped with an Eppendorf microinjector and manipulator, a Leica S9D stereomicroscope (with 10x, 20x and 40x objectives), a Gene Pulser Xcell Total System (100/240 V, 50/60 Hz) and an electroporator. In addition, all mice produced through the GEMM team are housed in Tecniplast Digital Ventilated Cages to ensure maximum health monitoring.
The GEMM team offers the following services: